KRas G12D inhibitors

US11964989B2 · kind B2 · utility

Assignees

• Mirati Therapeutics, Inc. · US
• Array BioPharma, Inc. · US

Inventors

• Xiaolun Wang · San Diego, US
• Aaron Craig Burns · San Diego, US
• James Gail Christensen · San Diego, US
• John Michael Ketcham · San Diego, US
• John David Lawson · San Diego, US
• Matthew Arnold Marx · San Diego, US
• Christopher Ronald Smith · San Diego, US
• Shelley Allen · Boulder, US
• James F. Blake · Longmont, US
• Mark Joseph Chicarelli · Boulder, US
• Joshua Ryan Dahlke · Boulder, US
• Donghua Dai · Boulder, US
• Jay Bradford Fell · Boulder, US
• John P. Fischer · Boulder, US
• Macedonio J. Mejia · Denver, US
• Brad Newhouse · Boulder, US
• Phong X. Nguyen · Placentia, US
• Jacob Matthew O'Leary · Denver, US
• Spencer Pajk · Boulder, US
• Martha E. Rodriguez · Boulder, US
• Pavel Savechenkov · Boulder, US
• Tony P. Tang · Boulder, US
• Guy P.A. Vigers · Boulder, US
• Qian Zhao · Louisville, US
• Dean Russell Kahn · Boulder, US
• John Gaudino · Longmont, US
• Michael Christopher Hilton · Boulder, US

Key dates

• Filing date: Jul 20, 2022
• Grant date: Apr 23, 2024
• Expiry date: Jul 20, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.